| Jul 26 |
EU Rejection of Alzheimer’s Drug Is Another Disappointment for Biogen
|
| Jul 26 |
Biogen/Eisai's Alzheimer's Drug Leqembi Gets 'No Go' From European Drug Regulator's Advisory Panel, Cites Serious Side Events
|
| Jul 26 |
The Zacks Analyst Blog Highlights Sage Therapeutics, Biogen Agenus and BioMarin Pharmaceutical
|
| Jul 26 |
European committee says Alzheimer's treatment Leqembi shouldn't get marketing approval
|
| Jul 26 |
Biogen Stock Tumbles After European Regulators Unexpectedly Reject Alzheimer's Drug
|
| Jul 26 |
Leqembi voted down by European regulators
|
| Jul 26 |
Biogen-partnered Alzheimer’s therapy fails to clear EU hurdle
|
| Jul 26 |
Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union
|
| Jul 25 |
Analysts Estimate Biogen Inc. (BIIB) to Report a Decline in Earnings: What to Look Out for
|
| Jul 25 |
Sage and Biogen’s SAGE-324 shows no benefit in essential tremor trial
|
